Liquid biopsy: Tumor diagnosis and treatment monitoring in a blood test. Radmila Jankovic, PhD Institute for Oncology and Radiology of Serbia

Similar documents
Nuevas tecnologías basadas en biomarcadores para oncología

How To Get A Cell Print

Targeted Therapy What the Surgeon Needs to Know

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer

Metastatic breast cancer represents an incurable condition associated with an average survival time of 18 to 24 months.

Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns

Cancer: DNA Synthesis, Mitosis, and Meiosis

WHITE PAPER SEPT 2015

CellCelector : enabling fast automated image-based isolation of pure single CTCs for personalized therapy

An Update on Lung Cancer Diagnosis

Us TOO University Presents: Understanding Diagnostic Testing

Haematopoietic Chimerism Analysis after Allogeneic Stem Cell Transplantation

Report series: General cancer information

Breast cancer research and a changing treatment pathway

Robert Bristow MD PhD FRCPC

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

Molecular Diagnosis of Hepatitis B and Hepatitis D infections

Frequently Asked Questions About Ovarian Cancer

What is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:

targeted therapy a guide for the patient

ACUTE MYELOID LEUKEMIA (AML),

Oncology Insights Enabled by Knowledge Base-Guided Panel Design and the Seamless Workflow of the GeneReader NGS System

The following information is only meant for people who have been diagnosed with advanced non-small cell

Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?

bitter is de pil Linos Vandekerckhove, MD, PhD

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

Immuno-Oncology Model Application in the Preclinical Treatment Setting

How can we generate economic value from personalized medicine and big data analysis?

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical

One out of every two men and one out of every three women will have some type of cancer at some point during their lifetime. 3

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

Mechanism Of Action of Palbociclib & PFS Benefit

Data Analysis for Ion Torrent Sequencing

New Advances in Cancer Treatments. March 2015

CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA

Adjuvant Therapy for Breast Cancer: Questions and Answers

How To Treat Mesothelioma With A Tumor Stem Cell Inhibitor

SAMO FoROMe Post-ESMO 2013 Breast Cancer

Theories on Metastasis: Innovative Thinking An Advocacy Perspective

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing

IKDT Laboratory. IKDT as Service Lab (CRO) for Molecular Diagnostics

SUMMARY. Randolph Fillmore, Florida Science Communications

PROJECT GROUP FOR AUTOMATION IN MEDICINE AND BIOTECHNOLOGY IN MANNHEIM BIOPROCESS ENGINEERING


Ef#icient Isolation and Accurate In Situ Analysis of Circulating Tumor Cells Using Detachable Beads and a High- Pore- Density Filter

Prostate Cancer. Treatments as unique as you are

Cytotoxic and Biotherapies Credentialing Programme Module 2

ESMO 2014 Summary Breast Cancer

Avastin in breast cancer: Summary of clinical data

Comparing Immunotherapy with High Dose IL-2 and Ipilimumab

Breast Cancer Care & Research

CANADIAN RULE BASED CLASSIFICATION SYSTEM (IVDD) Life Sciences British Columbia NRC-Industry Research Assistance Program

OBJECTIVES By the end of this segment, the community participant will be able to:

Avastin in breast cancer: Summary of clinical data

Prognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.

7. Prostate cancer in PSA relapse

AIDS IN IDENTIFYING CANDIDATES FOR HER2-TARGETED THERAPY

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins

THE LIQUID BIOPSY: fact or fiction? Marc Ramael

micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved

2015 ASCO Conference Highlights for PCa Patients: May 29-June 2 Chicago, IL. Howard R. Soule, PhD

An Introduction to PROSTATE CANCER

Pharmacogenetic Activities in SWOG Breast Cancer

Update in Hematology Oncology Targeted Therapies. Mark Holguin

LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH

Lymph Nodes and Cancer What is the lymph system?

Molecular markers and clinical trial design parallels between oncology and rare diseases?

Monoclonal Antibodies in Cancer. Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc.

A Letter from MabVax Therapeutics President and Chief Executive Officer

Opportunities and Challenges in Translating Novel Discoveries into Useful Clinical Tests

Brain Cancer. This reference summary will help you understand how brain tumors are diagnosed and what options are available to treat them.

Biofocus Molecular Diagnostic Panel

Summary & Conclusion

Understanding CA 125 Levels A GUIDE FOR OVARIAN CANCER PATIENTS. foundationforwomenscancer.org

Using genetic biomarkers to pre-identify oncology patients for clinical trials

BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I

Genetic diagnostics the gateway to personalized medicine

Understanding Metastatic Disease

FastTest. You ve read the book now test yourself

GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE

Molekylært målrettet medicinsk kræftbehandling for klinikere principper og metoder

Lung cancer is not just one disease. There are two main types of lung cancer:

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Now and the Future

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds

2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders

How To Make Cancer A Clinical Sequencing

Introduction Breast cancer is cancer that starts in the cells of the breast. Breast cancer happens mainly in women. But men can get it too.

Acute myeloid leukemia (AML)

Understanding series. new. directions LungCancerAlliance.org. A guide for the patient

Uses of Flow Cytometry

Blood-Based Cancer Diagnostics

A customizable ADCC assay service for antibodies & fusion proteins.

Future Directions in Cancer Research What does is mean for medical physicists and AAPM?

Cancer is the leading cause of death for Canadians aged 35 to 64 and is also the leading cause of critical illness claims in Canada.

Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs

From cells to therapeuticsvivalis. Humalex Fully human antibody discovery platform An integrated therapeutic development offering

Progress and Prospects in Ovarian Cancer Screening and Prevention

Pharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain

Targeted Therapies in Lung Cancer

Outline. Predictive Assays in Radiation Therapy Immunotherapy in Cancer Treatment. Introduction. Current clinical practice

Transcription:

Liquid biopsy: Tumor diagnosis and treatment monitoring in a blood test Radmila Jankovic, PhD Institute for Oncology and Radiology of Serbia

Term Liquid biopsy stands for: Circulating tumor cells (CTCs) Cell-free DNA (cfdna) Plasma Serum Other liquid material Exosomes

etiology Circulating tumor cells (CTCs) disseminated cancer cells cancer stem cells rare cells in a dormant, nonproliferative state unaffected by chemotherapy unrecognized by the host immune system difficult to isolate advanced cancer has less then 10 CTCs per 7.5ml of blood

Origin of CTCs (Paterlini-Brechot et al. Cancer Letters 2007. 253:180.)

Main approaches for CTC detection

Immunomagnetic Capture composite CD45 control cytokeratin DAPI Anti- EpCAM Ferrofluid Anti - CD45-APC Nucleus DAPI EpCAM Nucleus DAPI CD45 CK Anti- CK-PE Circulating Tumor Cell Leukocyte CellSearch System

Individual Cell Sorting with DEPArray Recovery Parking Main chamber 1. Inject, trap and image all cells 2. Move all cells of interest into Parking chamber 3. Move separately to Recovery chamber and flush Features Multiparametric image-based sorting Single cell resolution Small cell loads Gentle on cells No a priori thresholds choose best cells Sorting based on slow kinetics (10-100s minutes) possible p. 7

In vivo isolation of circulating tumor cells from peripheral blood of cancer patients Saucedo-Zeni N et al, Int J Oncol. 2012 Oct; 41(4): 1241 1250.

Microtube surface is coated with both E-selectin and antiepithelial antibodies (EpCAM or PSMA) Halloysite Nanotube Protein G E-Selectin-Fc Chimera Anti-EpCAM/PSMA mab

Clinical relevance of CTCs in breast cancer Applications Prognosis Monitor Metastasis Drug Activity Cell culture Xenograft Model Approaches Enumeration Molecular characterization DNA/RNA NGS Sequencing

% patients at or above the CTC threshold 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 20 30 40 50 100 1000 Baseline enumeration in MBC 75 70 71% healthy volunteers (n = 145) 65 61% benign diseases (n = 200) 60 58% 55% cancer, baseline (n = 177) 55 53% 49% cancer, first follow-up (n = 163) 50 47% 46% 45% 45 42% 40% 40 38% 38% 35% 36% 34% 34% 34% 35 32% 30% 29% 30 28% 26% 27% 24% 25 23% 23% 23% 22% 23% 21% 21% 20% 21% 21% 20 15% 16% 15 13% 13% 10 8% 8% 5 6% 3% 0 1% 1% CTC threshold (per 7.5 ml blood)

Beyond the enumeration: Is the CTC count relevant for development & progression of metastases?

The independent prognostic effect of CTC count on progression-free survival and overall survival. CTC count also improves the prognostication of metastatic breast cancer when added to full clinicopathological predictive models, whereas serum tumour markers do not.

Beyond the enumeration: Is the CTC count relevant for therapy efficacy monitoring? Study confirms the prognostic significance of CTCs in patients with MBC receiving first-line chemotherapy. For patients with persistently increased CTCs after 21 days of first-line chemotherapy, early switching to an alternate cytotoxic therapy was not effective in prolonging OS. Negative study?

Beyond the enumeration: Molecular characterization of CTCs Nat Genet 2013 Dec;45(12):1415-6. doi: 10.1038/ng.2831. The search for ESR1 mutations in breast cancer. Oesterreich S, Davidson NE

Term Liquid biopsy stands for: Circulating tumor cells (CTC) Cell-free DNA (cfdna) Plasma Serum Other liquid material Exosomes

Origin of Circulating Tumour DNA (ctdna) What is ctdna? ctdna is tumour DNA that has been shed into the bloodstream ctdna can be present in 0.01% - >90% of the total Cell Free DNA (cfdna) The amount of ctdna is related to the tumour burden and varies between patients with different clinical presentations Diaz and Bardelli, 2014 Journal of Clincial Oncology 32

Clinical relevance of ctdna Applications: Tumor genotyping: Tissue versus liquid biopsy Monitoring tumor burden, therapeutic response and treatment Minimal residual disease monitoring and early detection Approaches: PCR-based approaches Nested real-time PCR PARE ARMS-Scorpion PCR PAP-A amplification BEAMing Microfluidic digital PCR Droplet-based digital PCR NGS-based approaches Targeted deep sequencing Tam-Seq Safe-Seq CAPP-Seq Ion-AmpliSeq TM Whole exome sequencing Whole genome Sequencing 19

FFPE vs. ctdna FFPE Samples Problems with quality of DNA due to fixation Mixture of normal and tumour DNA Some patients have no tumour sample available The sample represents the tumour at one fixed time point ctdna Samples ctdna shed directly from tumour Extracted from the plasma component of whole blood Large fragment sizes possible Small quantities extracted ~ 30ng/ 5ml plasma Serial samples can be taken at various time points during the patient s treatment

Isolation and processing of ctdna Blood sample taken Sample spun down to isolate the plasma Plasma is stored at -80ºc Applications:: Next-generation sequencing Quantative PCR BEAMing Digital PCR ctdna is extracted from the plasma using the QIAamp Circulating Nucleic Acid or some other commercial kit Major techical advantage compared to CTC

Possible problems? ctdna is unstable: requires fast processing Getting only 30ng of ctdna per 5ml plasma extraction The technique used must be sensitive enough to pick up the low level variants Diaz and Bardelli, 2014 Journal of Clincial Oncology 32

What is Droplet Digital PCR? ctdna: methods Expensive equipment?

ctdna for monitoring metastasis This proof-of-concept analysis showed that circulating tumor DNA is an informative, inherently specific, and highly sensitive biomarker of metastatic breast cancer

ctdna for monitoring drug resistance Exome-wide analysis of circulating tumour DNA could complement current invasive biopsy approaches to identify mutations associated with acquired drug resistance in advanced cancers. Serial analysis of cancer genomes in plasma constitutes a new paradigm for the study of clonal evolution in human cancers.

ctdna as biomarkers of microscopic residual disease after surgery? Study demonstrates accurate mutation detection in tumor tissues using ddpcr, and that ptdna can be detected in blood before and after surgery in patients with early-stage breast cancer. ptdna could identifies patients at risk for recurrence, which could guide chemotherapy decisions for individual patients.

CTCs or ctdna? Daniel A. Haber, and Victor E. Velculescu Cancer Discovery 2014;4:650-661 2014 by American Association for Cancer Research Complementary roles as cancer biomarkers!

Term Liquid biopsy stands for: Circulating tumor cells (CTC) Cell-free DNA (cfdna) Plasma Serum Other liquid material Exosomes

Tumor signatures in the blood, Nature Biotechnology, 32, 2014 Thank you for you attention!